This invention provides a compound of the formula (I): wherein A and B are independently CR.sup.12 or N; D and E are each independently CR.sup.9 or N; R.sup.1 represents (C.sub.1-C.sub.6)alkyl; R.sup.2 represents hydrogen, halogen, hydroxy, (C.sub.1-C.sub.6)alkyl, halo(C.sub.1-C.sub.6)alkyl, hydroxy(C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkoxy or (C.sub.1-C.sub.6)alkoxy-(C.sub.1-C.sub.6)alkyl; R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.10 and R.sup.11 each independently represent hydrogen, halogen, (C.sub.1-C.sub.6)alkyl, halo(C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkoxy, hydroxy(C.sub.1-C.sub.6)alkyl or (C.sub.1-C.sub.6)alkoxy-(C.sub.1-C.sub.6)alkyl; or R.sup.3 and R.sup.4 are taken together with the carbon atom to which they are attached to form a 3- to 7-membered carbocyclic ring or heterocyclic ring in which one or two non-adjacent carbon atoms are optionally replaced by an oxygen atom, a sulfur atom or NH; R.sup.7 and R.sup.9 each independently represent hydrogen, halogen, (C.sub.1-C.sub.6)alkyl, halo(C.sub.1-C.sub.6)alkyl, hydroxy(C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkoxy, hydroxy(C.sub.1-C.sub.6)alkoxy, (C.sub.1-C.sub.6)alkoxy-(C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkoxy-(C.sub.1-C.sub.6)alkoxy, (C.sub.1-C.sub.6)alkylthio, (C.sub.1-C.sub.6)alkylsulfinyl, (C.sub.1-C.sub.6)alkylsulfonyl, NH.sub.2, [(C.sub.1-C.sub.6)alkyl]NH--, [(C.sub.1-C.sub.6)alkyl].sub.2N--, H.sub.2N--(C.sub.1-C.sub.6)alkoxy, (C.sub.1-C.sub.6)alkyl-NH--(C.sub.1-C.sub.6)alkoxy, [(C.sub.1-C.sub.6)alkyl].sub.2N(C.sub.1-C.sub.6)alkoxy; H.sub.2N--(C.sub.1-C.sub.6)alkoxy-(C.sub.1-C.sub.6)alkyl, (C.sub.1C.sub.6)alkyl-NH--(C.sub.1-C.sub.6)alkoxy-(C.sub.1-C.sub.6)alkyl, [(C.sub.1-C.sub.6)alkyl].sub.2N(C.sub.1-C.sub.6)alkoxy-(C.sub.1-C.sub.6)a- lkyl or 5- or 6-membered heterocyclic ring containing at least one nitrogen atom; R.sup.8 represents halogen, (C.sub.1-C.sub.6)alkyl, halo(C.sub.1-C.sub.6)alkyl, hydroxy(C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkoxy, hydroxy(C.sub.1-C.sub.6)alkoxy, (C.sub.1-C.sub.6)alkoxy-(C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkoxy-(C.sub.1-C.sub.6)alkoxy, halo(C.sub.1-C.sub.6)alkylsulfonyl, halo(C.sub.1-C.sub.6)alkylsulfinyl, halo(C.sub.1-C.sub.6)alkoxy, halo(C.sub.1-C.sub.6)alkylthio, [(C.sub.1-C.sub.6)alkyl]NH-- or [(C.sub.1-C.sub.6)alkyl].sub.2N--; or R.sup.7 and R.sup.8, when E is CR.sup.9, are taken together with the carbon atoms to which they are attached form a 5-8 membered carbocyclic or heterocyclic ring, in which one or two non-adjacent carbon atoms are optionally replaced by oxygen, sulfur, N or NH groups, wherein the carbocyclic ring or the heterocyclic ring is unsubstituted or substituted with one or more substituents each independently selected from the group consisting of hydroxy, (C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkoxy and hydroxy(C.sub.1-C.sub.6)alkyl; and R.sup.12 represents hydrogen, halogen, (C.sub.1-C.sub.6)alkyl or hydroxy(C.sub.1-C.sub.6)alkyl; or a pharmaceutically acceptable salt or solvate thereof. These compounds are useful for the treatment of disease conditions caused by overactivation of VR1 receptor such of pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.

 
Web www.patentalert.com

< Heterocyclic compounds as inhibitors of factor VIIa

< Aporphine and oxoaporphine compounds and pharmaceutical use thereof

> Treatment with omega-3 fatty acids and PPAR agonist and/or antagonist and a combination product thereof

> Method and apparatus for computer modeling a joint

~ 00288